Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1R9KZ
|
|||
| Drug Name |
BBP-711
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Primary hyperoxaluria type 1 [ICD-11: 5C51.20] | Phase 1 | [1] | |
| Company |
Cantero Therapeutics San Francisco, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 2-Hydroxyacid oxidase 1 (HAO1) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04876924) A Phase 1, Randomized, Double-Blinded, Placebo-controlled, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of BBP-711 (ORF-229) in Healthy Adult Subjects. U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.